financetom
Business
financetom
/
Business
/
Tronox's Recovery in Operating Rates Likely to Drive EBITDA Growth in 2025, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tronox's Recovery in Operating Rates Likely to Drive EBITDA Growth in 2025, UBS Says
Oct 10, 2024 11:25 PM

02:58 PM EDT, 10/10/2024 (MT Newswires) -- Tronox Holdings ( TROX ) is likely to see an increase in earnings before interest, taxes, depreciation, and amortization next year amid a recovery in operating rates representing a tailwind of $55 million into 2025, UBS Securities said in a note on Thursday.

The company is expected to benefit from higher titanium dioxide pricing and potential demand recovery driven by interest rate cuts and China's stimulus measures, according to the note.

"Interest rate cuts and potential China stimulus could be a catalyst for eventual restocking [of titanium dioxide], while duties in Europe add upward bias to pricing," UBS said.

More than 50% of Tronox's ( TROX ) sales in markets are shielded from Chinese supply through tariffs in the US, and potential protections in Europe, Brazil, and India could boost pricing power and provide a tailwind for earnings, UBS added.

These factors will likely result in EBITDA of around $800 million in 2025, up $200 million from a year earlier, UBS said.

The firm expects that Tronox's ( TROX ) free cash flow will improve by $200 million and exceed $300 million annually due to a decrease in capital expenditures following a period of high spending, operational improvements and cost-saving initiatives.

UBS upgraded its rating on Tronox's ( TROX ) stock to buy from neutral and increased the price target to $19 from $17.

Shares of the company were up 5.3% in recent trading.

Price: 14.37, Change: +0.72, Percent Change: +5.27

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
America Movil Increases Stake in ClaroVTR to 91%
America Movil Increases Stake in ClaroVTR to 91%
Jun 24, 2024
09:48 AM EDT, 06/24/2024 (MT Newswires) -- America Movil ( AMX ) said Monday it has increased its stake in ClaroVTR, its joint venture with Liberty Latin America, to 91%. The company said it increased its ownership by converting its outstanding notes held in ClaroVTR into equity. Financial terms of the increase weren't disclosed. Liberty Latin America will own the...
VCI Global to Invest $30 Million in TalkingData Group Holding
VCI Global to Invest $30 Million in TalkingData Group Holding
Jun 24, 2024
09:45 AM EDT, 06/24/2024 (MT Newswires) -- VCI Global ( VCIG ) said Monday that it signed an agreement to invest up to $30 million in TalkingData Group Holding, which provides big data analytics and artificial intelligence-powered solutions in Asia. The investment will make VCI Global ( VCIG ) a substantial shareholder of TalkingData Group and grant VCI Global (...
US Supreme Court takes up 'Dewberry' trademark dispute
US Supreme Court takes up 'Dewberry' trademark dispute
Jun 24, 2024
WASHINGTON (Reuters) - The U.S. Supreme Court on Monday agreed to decide a $43 million dispute between two real estate developers - one in Virginia and one in Georgia - over the rights to the Dewberry name in a case exploring when courts can award a company's profits as a remedy for trademark infringement. The justices took up an appeal...
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Jun 24, 2024
Monday, Alnylam Pharmaceuticals Inc ( ALNY ) revealed topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for ATTR amyloidosis with cardiomyopathy (ATTR-CM). ATTR-CM is a type of heart muscle disease that occurs when amyloid fibrils – clumps of misfolded proteins – are deposited into heart tissue and cause it to stiffen. Also...
Copyright 2023-2026 - www.financetom.com All Rights Reserved